biology

Polatuzumab vedotin

Polatuzumab vedotin is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Polatuzumab vedotin rather than just read about it. In short: Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin.

Key takeaways

Polatuzumab vedotin belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Polatuzumab vedotin to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Polatuzumab vedotin from memory before moving on to harder problems.

Reference excerpt

Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin. It was developed by the Genentech subsidiary of Roche. The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia. Polatuzumab vedotin was approved for medical use in the United States in June 2019, in Australia in October 2019, in the European Union in January 2020, and in Canada in November 2020.

Medical uses Polatuzumab vedotin is indicated in combination with bendamustine and a rituximab product for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adults with previously untreated diffuse large B-cell lymphoma (DLBCL).

History Polatuzumab vedotin was discovered by a team at Genentech led by Dan Eaton, Fred de Sauvage, and Andy Polson, who had been trying to develop ADCs for solid tumors without success, and in 2002 turned to blood cancers. In June 2019, polatuzumab vedotin was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product, to treat adults with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. The US Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product. The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567) that was conducted in the United States, Canada, Europe, and Asia. Participants in the trial had lymphoma that came back or did not improve after prior treatment. The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Polivy to Genentech. Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018. In March 2022, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended Polatuzumab vedotin, in combination with R-CHP or R-CHOP, as a primary treatment. A systematic meta-analysis of randomized trials and real-world evidence confirmed results of Pola-R-CHP. In February 2023, polatuzumab vedotin was recommended by the National Institute for Health and Care Excellence (NICE) to be used in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) for untreated diffuse large B-cell lymphoma (DLBCL). In April 2023, the FDA approved polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for people with previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma who have an International Prognostic Index score of two or greater.

Society and culture

Names Polatuzumab vedotin is the international nonproprietary name and the United States Adopted Name. Genentech included "Pol" in the generic and trade names in honor of Andy Polson, one of the scientists who discovered the drug.

References

Worked examples

Example 1 — a first encounter with Polatuzumab vedotin

Start with the simplest possible case. Write down what Polatuzumab vedotin claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Polatuzumab vedotin before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Polatuzumab vedotin ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Polatuzumab vedotin

In research: Polatuzumab vedotin appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Polatuzumab vedotin in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Polatuzumab vedotin is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antibody–drug conjugate, Drugs developed by Genentech, Drugs developed by Hoffmann-La Roche, so understanding it makes those chapters shorter.
In everyday life: Look for Polatuzumab vedotin outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Polatuzumab vedotin” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Polatuzumab vedotin in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Polatuzumab vedotin means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Polatuzumab vedotin out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Polatuzumab vedotin in simple terms?

Why does Polatuzumab vedotin matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Polatuzumab vedotin?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Polatuzumab vedotin.